0 218

Cited 0 times in

Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Intracranial Stenting or Flow-Diverter Treatment for Unruptured Cerebral Aneurysms: A Single-Center Cohort Study

Authors
 K Y Park  ;  T Ozaki  ;  A Kostynskyy  ;  H Kortman  ;  A Hilario  ;  P Nicholson  ;  R Agid  ;  T Krings  ;  V M Pereira 
Citation
 AMERICAN JOURNAL OF NEURORADIOLOGY, Vol.42(9) : 1638-1644, 2021-09 
Journal Title
AMERICAN JOURNAL OF NEURORADIOLOGY
ISSN
 0195-6108 
Issue Date
2021-09
MeSH
Clopidogrel / therapeutic use ; Cohort Studies ; Embolization, Therapeutic* ; Female ; Humans ; Intracranial Aneurysm* / diagnostic imaging ; Intracranial Aneurysm* / therapy ; Middle Aged ; Platelet Aggregation Inhibitors / therapeutic use ; Retrospective Studies ; Stents ; Ticagrelor / therapeutic use ; Treatment Outcome
Abstract
Background and purpose: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms. This study evaluated the efficacy and safety of ticagrelor versus clopidogrel for stent-assisted coiling or flow-diversion treatment in patients with unruptured cerebral aneurysms.

Materials and methods: From November 2003 to February 2019, two hundred one patients (mean age, 57.5 years; 156 women) with 233 unruptured aneurysms underwent stent-assisted coiling or flow-diversion treatment. All patients received antiplatelet therapy of aspirin plus clopidogrel (clopidogrel group, 121 patients with 140 aneurysms) or aspirin plus ticagrelor (ticagrelor group, 80 patients with 93 aneurysms). The clinical and radiologic data in each group were retrospectively reviewed and compared.

Results: Two hundred thirty-six procedures were performed, including stent-assisted coiling (n = 101) and flow diversion (n = 135). At 90 days, the primary outcome-a composite of any stroke and death-occurred in 9.9% of the clopidogrel group and 8.6% of the ticagrelor group (P = .822). Ischemic stroke occurred in 10 (7.0%) of the clopidogrel group and 7 (7.5%) of the ticagrelor group (P > .999). Disabling stroke occurred in 4 (2.8%) in the clopidogrel group and in 4 (4.3%) in the ticagrelor group (P = .716). Ninety-day death occurred in 3 (2.1%) in the clopidogrel group and 1 (1.1%) in the ticagrelor group (P > .999). Any bleeding at 90 days occurred in 13 (9.2%) in the clopidogrel group and 6 (6.5%) in the ticagrelor group (P = .479).

Conclusions: Ticagrelor appears to be as effective and safe as clopidogrel in stent-assisted coiling or flow-diversion treatment for unruptured cerebral aneurysms.
Full Text
http://www.ajnr.org/content/42/9/1638.long
DOI
10.3174/ajnr.A7216
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
Yonsei Authors
Park, Keun Young(박근영)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/187032
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links